Website pharmacygeoff.md sells unapproved, misbranded prescription drugs, including COVID-19 claims, to U.S. consumers.
What happened
FDA reviewed the website www.pharmacygeoff.md on March 22, 2021. FDA found the site offering prescription drugs for sale to U.S. consumers, including hydroxychloroquine (Plaquenil), chloroquine (Lariago-DS), lopinavir/ritonavir (Hivus-LR, Lopimune), ribavirin (Ribasure) and dexamethasone (Dexona), with claims they treat COVID-19 and other diseases. FDA said there were no FDA-approved applications for these products as offered, and that the site did not require a prescription.
What FDA found
The site sells new drugs that FDA has not approved for these uses.
Section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]The site puts unapproved drugs into interstate commerce.
Section 301(d) of the FD&C Act [21 U.S.C. § 331(d)]The drug labeling lacks adequate directions for use, so a layperson cannot use the products safely.
Section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5The site offers prescription drugs without requiring a prescription.
Sections 503(b)(1) and 301(k) of the FD&C Act [21 U.S.C. § 353(b)(1), § 331(k)]
What FDA wants
FDA asks the company to stop selling the unapproved and misbranded products and, within 48 hours, email FDA the specific steps taken to fix the violations and prevent them from recurring, with supporting documents. If corrective action cannot be finished in that time, the company must explain the delay and say when it will be done.
Who should pay attention
- online pharmacies and websites that ship prescription drugs to U.S. consumers
- companies making COVID-19 treatment claims for unapproved products
- makers of brand-name drugs whose names appear on such sites
This is a summary. Read the original letter on fda.gov.